Why Moderna Inc (MRNA) Stock Is Rising
As of 2026-09-01, Moderna Inc (MRNA) has a next-year EPS growth estimate of 42.33%. Featured in 4 EPS revision reports, most recently on 2026-07-07.
Why MRNA Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Moderna Inc's next-year EPS growth estimate from 41.15% to 41.67% on 2026-08-28.
- →Estimate Trending Higher: Since detection, the estimate has moved up a net +0.66 pp to 42.33% across 1 upward revision.
- ·Current-Year Growth: Projected at -16.56%, supporting the forward estimate revision.
News Context
The primary structural driver is the upward revision to Moderna’s next-year EPS growth estimate, which rose from 41.15% to 41.67% on Aug 28 and has since climbed to 42.33%. Headlines highlight Moderna leading the S&P 500 in August and being among the month’s best-performing stocks, but none cite a specific earnings beat, contract win, guidance raise, or product launch. The continued upward drift in the estimate suggests analyst momentum has extended beyond the initial upgrade.
Generated 2026-09-01 · news as of 2026-09-01
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 42.33%
- EPS growth this year
- -16.56%
- EPS next quarter (est)
- -$1.16
- Last price
- $140.34
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-01 | 42.33% | -16.56% | -$1.16 | $140.34 |
| 2026-08-31 | 42.33% | -16.56% | -$1.16 | $140.34 |
| 2026-08-30 | 41.67% | -16.56% | -$1.16 | $137.99 |
| 2026-08-29 | 41.67% | -16.56% | -$1.16 | $137.99 |
| 2026-08-28 | 41.67% | -16.56% | -$1.16 | $137.99 |
| 2026-08-27 | 41.15% | -16.57% | -$1.16 | $142.77 |
| 2026-08-26 | 41.84% | -16.57% | -$1.16 | $149.66 |
| 2026-08-25 | 41.78% | -16.52% | -$1.16 | $158.83 |
| 2026-08-24 | 42.23% | -16.92% | -$1.16 | $138.89 |
| 2026-08-23 | 42.58% | -17.04% | -$1.16 | $145.13 |
| 2026-08-21 | 42.58% | -17.04% | -$1.16 | $145.13 |
| 2026-08-20 | 42.56% | -17.04% | -$1.16 | $133.32 |
| 2026-08-19 | 42.56% | -17.04% | -$1.16 | $174.38 |
| 2026-08-18 | 42.55% | -17.04% | -$1.16 | $62.96 |
| 2026-08-17 | 42.55% | -17.04% | -$1.16 | $64.46 |
| 2026-08-16 | 42.55% | -17.04% | -$1.16 | $63.32 |
| 2026-08-14 | 42.55% | -17.04% | -$1.16 | $63.32 |
| 2026-08-13 | 42.55% | -17.04% | -$1.16 | $63.65 |
| 2026-08-12 | 42.55% | -17.04% | -$1.16 | $63.67 |
| 2026-08-11 | 42.76% | -16.71% | -$1.16 | $60.57 |
| 2026-08-10 | 42.76% | -16.71% | -$1.16 | $59.81 |
| 2026-08-09 | 42.76% | -16.71% | -$1.16 | $59.17 |
| 2026-08-07 | 42.76% | -16.71% | -$1.16 | $59.17 |
| 2026-08-06 | 42.68% | -16.70% | -$1.16 | $53.86 |
| 2026-08-05 | 42.68% | -16.70% | -$1.16 | $56.26 |
| 2026-08-04 | 42.68% | -16.70% | -$1.16 | $56.99 |
| 2026-08-03 | 42.49% | -17.52% | -$1.19 | $55.14 |
| 2026-08-02 | 45.10% | -20.49% | -$1.38 | $54.82 |
| 2026-07-31 | 45.73% | -19.96% | -$1.98 | $54.82 |
| 2026-07-30 | 44.93% | -19.36% | -$2.03 | $57.92 |
Reports Featuring MRNA
- 2026-07-07
WBX +40.8% Leads EPS Revision Winners; NMAX Surges on 217.8pp EPS Upgrade
- 2026-07-06
Stock Surge Alert: WBX +47%, IOT +29%, MRNA +22% on EPS Revisions
- 2026-07-02
Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
- 2026-07-01
Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
Recent News
- These ETFs capture some of the biggest market moves in AugustMarketWatch
- Moderna Led the S&P 500 in August as Edison International SankBarrons.com
- 22 best-performing stocks of August, as the software industry continues its recoveryMarketWatch
- Six stocks are on pace for their best month on recordMarketWatch
- BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt BMO Capital Terms It Clear SetbackStocktwits
- BioNTech Stock Falls on Cancer Vaccine SetbackBarrons.com
- BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrastInvesting.com
- Moderna upgraded, Allstate downgraded: Wall Street's top analyst callsThe Fly
- Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccinesBioPharma Dive
- Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccinesBioPharma Dive
Screen Performance
Aggregate stats across all 2024 tickers our top-EPS-revision screen has flagged over the past 153 days.
- Median return since detection
- +1.8%
- % of tickers in the green
- 54%
- Median return on winners
- +20.3%
- Large revisions captured
- 1641
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Moderna Inc (MRNA) stock go up recently?▾
Moderna Inc (MRNA) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 41.15% to 41.67% on 2026-08-28. Since detection, the estimate has moved up a net +0.66 pp to 42.33%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Moderna Inc's next-year EPS growth estimate?▾
As of 2026-09-01, Moderna Inc (MRNA) has a next-year EPS growth estimate of 42.33%, based on analyst consensus.
When was the latest EPS estimate revision for MRNA?▾
The most recent revision occurred on 2026-08-31, when analysts adjusted the next-year EPS growth estimate from 41.67% to 42.33%.
What sector and industry does Moderna Inc belong to?▾
Moderna Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MRNA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Moderna Inc (MRNA) appears here because it was detected by our daily top-EPS-revision-performer screen.